Neurotrope, Inc. (NTRP): Price and Financial Metrics
GET POWR RATINGS... FREE!
NTRP Stock Price Chart Interactive Chart >
NTRP Price/Volume Stats
|Current price||$0.94||52-week high||$3.85|
|Prev. close||$1.05||52-week low||$0.68|
|Day high||$1.04||Avg. volume||597,206|
|50-day MA||$1.05||Dividend yield||N/A|
|200-day MA||$1.13||Market Cap||22.36M|
Neurotrope, Inc. (NTRP) Company Bio
Neurotrope, Inc., a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The company was founded in 2012 and is based in New York City, New York.
Most Popular Stories View All
NTRP Latest News Stream
|Loading, please wait...|
NTRP Latest Social Stream
View Full NTRP Social Stream
Latest NTRP News From Around the Web
Below are the latest news stories about Neurotrope Inc that investors may wish to consider to help them evaluate NTRP as an investment opportunity.
Neurotrope (NTRP) inks an agreement with BryoLogyx to supply synthetic Bryostatin-1, manufactured by Albany Molecular Research, for its clinical trials in Alzheimer's disease and other neurodegenerative disorders and commercial use, if approved.BryoLogyx will pay a fee on its gross sales of Bryostatin-1 for the treatment of acute lymphocytic leukemia ((ALL))...
BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia
Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced its entry into a strategic agreement with BryoLogyx Inc., www.BryoLogyx.com, for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Molecular Research, Inc. ("AMRI"), a leading global CDMO provider of advanced drug development and manufacturing solutions. Neurotrope expects to use the synthetic Bryostatin-1 in its clinical development initiatives aimed at advancing its lead product candidate for the treatment of Alzheimer's disease ("AD") and other neurodegenerative diseases and, ultimately, as a source for potential commercial drug supply if regulatory approval is received.
Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease
Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health (NIH) under a $2.7 million grant to Neurotrope. After reviewing the data from the previous trial with Key Opinion Leaders and the NIH, we designed a study to evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda® (memantine) in patients with AD. The Company has engaged Worldwide Clinical Trials to initiate site recruitment and activation.
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - WMGI, MINI, NTRP
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek ...
NTRP Price Returns